Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases

References

• Paulus W, Jellinger K, Morgello S, Deckert-Schliiter M. Tumours of the Haemopoietic System. In: Kleihues P, Cavenee WK. (eds) Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000; 198.
   Google Scholar
• Central Brain Tumour Registry of the United States: Statistical report: Primary Brain Tumours in the United States. 1997–2001. Chicago, IL: Central Brain Tumor Registry of The United States 2004–2005 (http://www.cbrtus.org).
   Google Scholar
• Montesinos-Rongen M, Kuppers R, Schluter D et al. Primary central nervous system lymphomas are derived from germinal center B cells and show a preferential usage of V4-34 gene segment. Am J Pathol 1999; 155: 2077–2086.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by abberant somatic hypermutation. Blood 2004; 103: 1869–1875.
   PubMed Web of Science ®Google Scholar
• Sekita T, Tamaru JI, Kaito K, Katayama T, Kobayashi M, MikataA. Primary central nervous system lymphomas Express Vh genes with intermediate to high somatic mutations. Leukemia and Lymphoma 2001; 41: 377–385.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Ziibleke-Jenisch R, Gesk S et al. Interphase cytogenetic analysis of lymphoma-associated chromo-somal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 2002; 61: 926–933.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central system lymphoma: Long-term outcome. J Neurosurg 1994; 81: 188–195.
   PubMed Web of Science ®Google Scholar
• Abrey LE, De Angelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–863.
   PubMed Web of Science ®Google Scholar
• Moreton P, Morgan GJ, Gilson D et al. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemother Pharmacol 2004; 53: 324–328.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Goldman DL, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognotive function. J Clin Oncol 1991; 9: 1580–1590.
   PubMed Web of Science ®Google Scholar
• Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: exprience with two cases and review of the literature. Onkologie 2003; 26: 351–354.
   PubMed Web of Science ®Google Scholar
• Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicology of high-dose cytarabine by 72 hour continuous infusion. Cancer Treat Rep 1986; 70: 1059.
   PubMedGoogle Scholar
• Reid JM, Pendergrass TW, Kralio MD, Hammond GD, Ames MM. Plasma Pharmacokinetics and cerebrospinal fluid concentra-tions of idarubicin and idarubicinol in pediatric patients: a Childrens Cancer Study Group report. Cancer Res 1990; 50: 6525–6528.
   PubMed Web of Science ®Google Scholar
• Hans NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases: report of the Clinical Advisory Committee Meeting. Airlie House, Virginia November 1997. Histopathology 2000; 36: 69–86.
   PubMedGoogle Scholar
• New P. Radiation injury to the nervous system. Curr Opin Neurol 2001; 14: 725–734.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H et al. Non-Hodgin's lymphoma of the brain. Can high dose, large—volume radiation therapy improve survival? Report on prospective trail by the Radiation Therapy Oncology Group (RTOG): RTOG: 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9–17.
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001; 80 (suppl 3): B113–117.
   PubMed Web of Science ®Google Scholar
• Jhanke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L. Agnieszka Korfel on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 2006; 80: 159–165.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Reni M, Dell'Oro S et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompe-tent patients. Oncology 2001; 60: 134–140.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188–195.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Deangelis LM, Yaholom J. Combined modality therapy for primary CNS lymphomas. J Clin Oncol 1992; 10: 635–643.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yaholom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. J Clin Oncol 2000; 18: 3144–3150.
   PubMed Web of Science ®Google Scholar
• Besselli EM, Graus F, Lopez-Guillermo A et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgin's lymphoma. Int JRad/at Oncol Biol Phys 2001; 50: 457–464.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with non-acquired immunodefficiency syndrome related central nervous system lymphoma: a pilot study of the BOMES protocol. Cancer 1998; 82: 1946–1951.
   PubMed Web of Science ®Google Scholar
• Stewart PA. Endothelial vesicles in blood-brain barrier: are they related to permeability? Cell Mol Neurobiol 2000; 20: 149–163.
   PubMed Web of Science ®Google Scholar
• Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temazolamide for central nervous system lymphomas. Cancer 2004; 101: 139–145.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenburg J et al. Rituximab therapy for CNS llymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466–468.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Kawada H, Iwaki Y et al. Measuremant of rituximab concentration in the cerebrospinal fluid in CNS lymphoma. Rinsho Ketsueki 2004; 45: 1255–1257.
   PubMedGoogle Scholar
• Schulz H, Pels H, Wolf-Schmidt I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti CD20 antibody rituximab. Haematologica 2004; 89: 753–754.
   PubMed Web of Science ®Google Scholar